How to invest in biotechnology: the healthcare sector’s high-growth area
Man doing science things
Biotech stocks

How to invest in biotechnology: the healthcare sector’s high-growth area

Dr Mike Tubbs provides an overview of this thriving industry, whose latest triumphs include the Covid-19 vaccines. He examines the best investment str…
14 May 2021
Vaccine patents: a bitter pill for drug companies
Nurse with a Covid vaccine
Biotech stocks

Vaccine patents: a bitter pill for drug companies

The US has suggested waiving drug companies’ vaccine patents to hasten the defeat of Covid-19, sending their share prices down.
14 May 2021
AstraZeneca’s shareholders rebel over pay
 © Chris Ratcliffe/Bloomberg via Getty Images
Biotech stocks

AstraZeneca’s shareholders rebel over pay

Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
14 May 2021
Merck: the good value biotech stock that has cornered the cancer market
Woman doing medicine things
Share tips

Merck: the good value biotech stock that has cornered the cancer market

Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.
27 Apr 2021
Activist investor Elliott takes takes a stake in Glaxo
GlaxoSmithKline office
Biotech stocks

Activist investor Elliott takes takes a stake in Glaxo

Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.
22 Apr 2021
Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold
People

Moderna’s Stéphane Bancel: the maths nerd who struck vaccine gold

A decade ago, Stéphane Bancel took a gamble and joined a fledgling start-up working on an unproven new technology. The gamble paid off with the rise o…
17 Apr 2021
How the vaccine wars will harm us all
Global Economy

How the vaccine wars will harm us all

Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …
27 Mar 2021
Cover of MoneyWeek magazine issue no 1022, Friday 23 October 2020

Subscribe to MoneyWeek and get your first six issues FREE

Subscribe to MoneyWeek now and get your first six magazine issues absolutely FREE
AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars
People

AstraZeneca’s Pascal Soriot: in the crossfire of the vaccine wars

AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time …
27 Mar 2021
Scientific-instrument companies are a global success – here's how to play them
Share tips

Scientific-instrument companies are a global success – here's how to play them

Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…
26 Mar 2021
Three winners of the long-term biotech boom
Share tips

Three winners of the long-term biotech boom

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…
22 Mar 2021
The unscientific criticism of AstraZeneca could do lasting damage
Biotech stocks

The unscientific criticism of AstraZeneca could do lasting damage

Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.
18 Mar 2021
Johnson & Johnson vaccine approval is another shot in the arm for the world
Biotech stocks

Johnson & Johnson vaccine approval is another shot in the arm for the world

Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports
4 Mar 2021
How to invest in the latest developments in hearing technology
Biotech stocks

How to invest in the latest developments in hearing technology

Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…
19 Feb 2021
Vanquishing the virus: the race to make vaccines for Covid-19
Biotech stocks

Vanquishing the virus: the race to make vaccines for Covid-19

The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…
12 Feb 2021
Vexing vaccine delays hit drug firms
Biotech stocks

Vexing vaccine delays hit drug firms

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021
AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion
Biotech stocks

AstraZeneca turns the tables as it acquires US pharmaceutical firm Alexion

AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…
17 Dec 2020
The lessons of “Operation Warp Speed” – the race to produce a vaccine
Biotech stocks

The lessons of “Operation Warp Speed” – the race to produce a vaccine

Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.
13 Dec 2020
The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers
Biotech stocks

The MoneyWeek Podcast: Barry Norris on why he's shorting vaccine-makers

The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…
3 Dec 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020
Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine
People

Ugur Sahin and Özlem Türeci : the boffins behind the Covid-19 vaccine

Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…
21 Nov 2020
Moderna’s “stunning” second vaccine
Biotech stocks

Moderna’s “stunning” second vaccine

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports
19 Nov 2020